
Claims

1. Use of a mutant isocitrate dehydrogenase 2 (IDH2) inhibitor in the manufacture of a medicament for treating acute myelogenous leukemia in a subject, wherein the mutant IDH2 is to be administered to the subject with azacitidine, the mutant IDH2 inhibitor is 2-methyl-1-[(4-[6-(trifluoromethyl)pyridin-2-yl]-6-{[2-(trifluoromethyl)pyridin-4-yl]amino}-1,3,5-triazin-2-yl)amino]propan-2-ol having the following formula:



or a pharmaceutically acceptable salt, solvate, tautomer, stereoisomer, isotopologue, or a polymorph thereof (COMPOUND 1), and wherein the acute myelogenous leukemia is characterized by the presence of a mutant allele of IDH2.

2. The use of claim 1, wherein the IDH2 mutation is an IDH2 R140Q or R172K mutation.

3. The use of claim 4, wherein the acute myelogenous leukemia newly diagnosed.

4. The use of any one of claims 1 to 3, wherein the dose of COMPOUND 1 is 20 to 2000 mg/day.

5. The use of any one of claims 1 to 4, wherein the dose of COMPOUND 1 is 50 to 500 mg/day.

6. The use of any one of claims 1 to 5, wherein the dose of COMPOUND 1 is about 50 mg/day.

7. The use of any one of claims 1 to 5, wherein the dose of COMPOUND 1 is about 100 mg/day.

8. The use of any one of claims 1 to 5, wherein the dose of COMPOUND 1 is about 200 mg/day.

9. The use of any one of claims 1 to 8, wherein the dose of azacitidine is 50 to 500 mg/m^2.

10. The use of any one of claims 1 to 9, wherein the dose of azacitidine is 50 to 200 mg/m^2.

11. The use of any one of claims 1 to 9, wherein the dose of azacitidine is about 50 mg/m^2.

12. The use of any one of claims 1 to 9, wherein the dose of azacitidine is about 60 mg/m^2.

13. The use of any one of claims 1 to 9, wherein the dose of azacitidine is about 75 mg/m^2.

14. The use of any one of claims 1 to 13, wherein COMPOUND 1 and azacitidine are to be administered concurrently.

15. The use of any one of claims 1 to 13, wherein COMPOUND 1 and azacitidine are to be administered sequentially.

16. A pharmaceutical composition, comprising 2-methyl-1-[(4-[6-(trifluoromethyl)pyridin-2-yl]-6-{[2-(trifluoromethyl)pyridin-4-yl]amino}-1,3,5-triazin-2-yl)amino]propan-2-ol, or a pharmaceutically acceptable salt, solvate, tautomer, stereoisomer, isotopologue, or a polymorph thereof, and azacitidine.

17. The use of claim 1, wherein the composition of claim 16 is to be administered to the patient.